Targeting key inflammatory mediators—such as the CCL2/CCR2 axis, CSF1R, or the IL-1β signaling pathway—has demonstrated promising anti-tumor effects in preclinical models (39, 40). This evidence concerns the gene CCL2 and neoplasm.